These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 9251584)

  • 41. Feasibility of using recipients of health promotional newsletters for post-marketing surveillance.
    Mead LA; Ford DE; Roht LH; Beach CL; Klag MJ
    J Clin Epidemiol; 2000 Jun; 53(6):653-60. PubMed ID: 10880786
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of long-term diltiazem administration on serum lipids in post-myocardial infarction survivors. Multicenter Diltiazem Post-Infarction Trial Research Group.
    Boden WE; Moss AJ; Herbert PN; Saritelli A; Oakes D; Eberly S
    Am J Cardiol; 1994 Mar; 73(7):513-4. PubMed ID: 8141095
    [No Abstract]   [Full Text] [Related]  

  • 43. Is crowdfunding a viable source of clinical trial research funding?
    Sharma A; Khan JS; Devereaux PJ
    Lancet; 2015 Jul; 386(9991):338. PubMed ID: 26227465
    [No Abstract]   [Full Text] [Related]  

  • 44. ["The safety of drugs a stepchild of medicine". Calcium blockers not the only example].
    Karlsson Y
    Lakartidningen; 1996 Oct; 93(43):3804-6. PubMed ID: 8965557
    [No Abstract]   [Full Text] [Related]  

  • 45. Noninferiority is (too) common in noninferiority trials.
    Soonawala D; Dekkers OM; Vandenbroucke JP; Egger M
    J Clin Epidemiol; 2016 Mar; 71():118-20. PubMed ID: 26607238
    [No Abstract]   [Full Text] [Related]  

  • 46. Societal responsibilities of clinical trial sponsors. Lack of commercial pay off is not a legitimate reason for stopping a trial.
    Evans S; Pocock S
    BMJ; 2001 Mar; 322(7286):569-70. PubMed ID: 11238141
    [No Abstract]   [Full Text] [Related]  

  • 47. Noninferiority is almost certain with lenient noninferiority margins.
    Flacco ME; Manzoli L; Ioannidis JP
    J Clin Epidemiol; 2016 Mar; 71():118. PubMed ID: 26607237
    [No Abstract]   [Full Text] [Related]  

  • 48. Diltiazem and mortality in myocardial infarction.
    Bittar G
    J Am Coll Cardiol; 1992 May; 19(6):1370. PubMed ID: 1564245
    [No Abstract]   [Full Text] [Related]  

  • 49. Non-commercial randomised clinical trials need money for meetings and travel expenses.
    Kunkler IH
    BMJ; 2003 Dec; 327(7427):1349. PubMed ID: 14656866
    [No Abstract]   [Full Text] [Related]  

  • 50. [IBM, money, calcium antagonists and bias].
    Hernborg A
    Lakartidningen; 1996 Nov; 93(46):4136. PubMed ID: 8984259
    [No Abstract]   [Full Text] [Related]  

  • 51. Clinician-trialist rounds: 12. When your grant gets turned down--part 2: resurrection.
    Szatmari P; Sackett DL
    Clin Trials; 2012 Oct; 9(5):660-3. PubMed ID: 23060324
    [No Abstract]   [Full Text] [Related]  

  • 52. Diltiazem prevents reinfarction--but how does it work?
    Am Pharm; 1986 Nov; NS26(11):15. PubMed ID: 3799452
    [No Abstract]   [Full Text] [Related]  

  • 53. Randomized clinical trials: enough bang for the buck?
    Strandness DE
    J Vasc Surg; 1991 Apr; 13(4):544-8. PubMed ID: 2010934
    [No Abstract]   [Full Text] [Related]  

  • 54. The perilous state of independent randomized clinical trials and related applied research in Canada.
    Yusuf S; Cairns J
    CMAJ; 2012 Dec; 184(18):1997-2002. PubMed ID: 22619342
    [No Abstract]   [Full Text] [Related]  

  • 55. Shall the pharmaceutical companies decide which trials to perform?
    Rogne S
    Tidsskr Nor Laegeforen; 2017 Feb; 137(3):183. PubMed ID: 28181752
    [No Abstract]   [Full Text] [Related]  

  • 56. Clinical trials and the public.
    Duley L
    J Evid Based Med; 2012 Nov; 5(4):192-3. PubMed ID: 23557498
    [No Abstract]   [Full Text] [Related]  

  • 57. How Canada can better embed randomized trials into clinical care.
    Murthy S; Fowler RA; Laupacis A
    CMAJ; 2020 Aug; 192(32):E928-E929. PubMed ID: 32732228
    [No Abstract]   [Full Text] [Related]  

  • 58. The Netherlands. Randomised trials.
    van Gijn J
    Lancet; 1996 May; 347(9010):1234-5. PubMed ID: 8622457
    [No Abstract]   [Full Text] [Related]  

  • 59. Trial re-investment to build better research for better impact.
    Fox TA; Horne GA; Craddock C; Cook G; O'Brien S; Fox S; Hockaday A; Silk G; Hillmen P
    Lancet; 2019 Aug; 394(10199):635-636. PubMed ID: 31448733
    [No Abstract]   [Full Text] [Related]  

  • 60. Re: Prospective reinfaction outcomes in the Thrombolytic Era Cardizem CD Trial (PROTECT).
    Goodman S; Langer A
    Can J Cardiol; 1997 Jul; 13(7):693, 696. PubMed ID: 9251584
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.